Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mast cell activation syndrome where neither an allergy or other underlying disease is association, nor KIT-mutated mast cells are detectable.
Biomarker and diagnostic research for idiopathic mast cell activation syndrome has been reported in the published literature.
No clinical trials have been registered for idiopathic mast cell activation syndrome.
3 publications have been identified in PubMed for idiopathic mast cell activation syndrome. Research spans Diagnostic / Biomarker (33%), Clinical Trial Publication (33%), and Basic Science / Preclinical (33%).
Asare-Bediako B (2026). [PMID: 41486419](https://pubmed.ncbi.nlm.nih.gov/41486419/). *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. [Basic Science / Preclinical]
Hormet Igde M (2025). [PMID: 40624779](https://pubmed.ncbi.nlm.nih.gov/40624779/). *Allergy and asthma proceedings*. [Clinical Trial Publication]
Zaroui A (2024). [PMID: 38444090](https://pubmed.ncbi.nlm.nih.gov/38444090/). *ESC heart failure*. [Diagnostic / Biomarker]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 6:57 PM UTC
AI-curated news mentioning idiopathic mast cell activation syndrome
Updated Jun 4, 2026
New insights into mast cell activation syndrome (MCAS) have emerged with the six-year update on the global consensus-2 diagnostic criteria. This progress aims to enhance diagnostic accuracy and patient management for those affected by this rare condition.